Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

ng of its strategic partnership for TB-403.

In the first half of 2009, gross profit amounted to EUR3.2 million. In the same period in 2008, ThromboGenics achieved a gross profit of EUR30.3 million due to the upfront payment from Roche mentioned earlier.

ThromboGenics invested EUR8.8 million in its R&D activities in the first six months of 2009. This compares with a spend on R&D of EUR11.6 million in the same period in 2008. This reduction in R&D spend was the result of the decision to capitalise the Phase III clinical trial costs relating to microplasmin for back of the eye disease. In the first half of 2009, EUR5.7 million of R&D costs were capitalized.

ThromboGenics general and administrative expenses increased to EUR1.7 million from EUR1.2 million due to higher (one-off) legal costs in part due to the merger of ThromboGenics NV with its subsidiary ThromboGenics Ltd.

In the first half of 2009, ThromboGenics reported an operating loss of EUR5.5 million. This compares with an operating profit of EUR17.3 million in the corresponding period in 2008, which resulted from the significant upfront payment received from Roche.

ThromboGenics achieved net financial income of EUR0.8 million in the first half of 2009. In the first half of 2008, the Company also had net financial income of EUR0.8 million.

In the first half of 2009, ThromboGenics had a pre-tax loss of EUR4.7 million. This compares with a pre-tax profit of EUR18.0 million in the first half of 2008. In both periods, ThromboGenics paid minimal tax expenses.

ThromboGenics reported a net loss of EUR4.7 million in the first half of 2009, giving a diluted loss per share of EUR0.17. This compares with a net profit of EUR18.0 million and diluted earnings per share of EUR0.67 in the first half of 2008.

Financial Position and Cash Flow

As of 30 June, ThromboGenics h
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 About POCT ... performed outside a clinical laboratory. It helps in ... appropriate treatments and medication. POCT is gaining popularity ... lifestyle diseases such as diabetes, heart disease, and ... devices are standardized to minimize errors during the ...
(Date:9/18/2014)... Worcester, Mass. (PRWEB) September 18, 2014 ... bore of an MRI scanner is currently being tested ... Brigham and Women's Hospital in Boston with the aim ... MRI images, can make prostate cancer biopsies faster, more ... The novel system also has the potential to deliver ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... 18, 2014 On Tuesday, Secretary of ... Jim Risch for National Lab Day on the Hill. ... the national laboratory system. Durbin and Risch also formally ... increase awareness of the reach of the national labs ... to address some of our nation's most pressing challenges. ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3
... and cell technologies have for the first time caught ... cells. The researchers, from the Walter and Eliza Hall ... Sydney (UTS), achieved this long-held aim using a combination ... platform new to Australia. The detailed look at ...
... Therapeutics, Inc. will present pancreatic cancer data based on Precision,s ... Clinical Oncology (ASCO) GI Symposium, January 20-22 in San Francisco, ... ASCO GI are titled, InVitro ... and Pattern of In Vitro Chemotherapy Response in Pancreatic ...
... ALCLS), announced today that scientists from Cellectis therapeutics, ... and Institut de la Vision (Paris) have used ... cultured cells by a Herpes Simplex virus (HSV-1). ... Molecular Therapy(1) (Mol. Ther. 2011, Jan 11. Epublication ...
Cached Biology Technology:Malaria parasite caught red-handed invading blood cells 2Malaria parasite caught red-handed invading blood cells 3Precision Therapeutics Announces Two Pancreatic Cancer Studies Emphasizing the Utility of ChemoFx® in Cancer Treatment Options 2Cellectis' Meganuclease Technology Used to Efficiently Prevent Viral Infection 2Cellectis' Meganuclease Technology Used to Efficiently Prevent Viral Infection 3
(Date:9/18/2014)... happy-go-lucky characters, so you might expect that most would ... fact some dogs are distinctly more pessimistic than others, ... "This research is exciting because it measures positive and ... offers researchers and dog owners an insight into the ... Melissa Starling, from the Faculty of Veterinary Science. Her ...
(Date:9/18/2014)... Elsevier, a world-leading provider of scientific, technical and ... Research Management Society (ARMS), recognized the academic research ... Scopus Young Researcher of the Year Awards. , ... National Convention Centre and in conjunction with the ... representing Australia,s and New Zealand,s scientific community. Guest ...
(Date:9/18/2014)... to 400 kilometres in search of a home, which makes ... spend their entire adult lives under the protection of their ... ocean, says study co-author, Dr Hugo Harrison from the ARC ... James Cook University. , "In the past we haven,t known ... glimpse into how far they can swim, crossing large tracts ...
Breaking Biology News(10 mins):Dogs can be pessimists too 2Dogs can be pessimists too 3Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Nemo's epic journey to find a new home 2
... have identified good bacteria already living in some humans ... infection. They report their findings today at the 2005 ... believe every life form has its natural enemy, and ... Tao, Associate Professor of the Department of Oral Biology, ...
... is inspiring cutting-edge research in the design of new ... A report about these exciting new results involving the ... the current issue of the scientific journal, Advanced Materials. ... of molecular, cellular and developmental biology at UCSB, and ...
... your backyard pond. Restrain yourself from ordering exotic pets ... look in the pictures. And vote for politicians that ... of the National Academy of Sciences article by Drs. ... defense in combating invasive animals is ensuring that they ...
Cached Biology News:Friendly bacteria in humans may protect against HIV 2Marine sponge yields nanoscale secrets 2Marine sponge yields nanoscale secrets 3Undesirable expatriates: Preventing the spread of invasive animals 2Undesirable expatriates: Preventing the spread of invasive animals 3
... The MyiQ detection system is used ... I, FAM, VIC, TET, or JOE fluorophores ... simultaneous collection of fluorescence data from 96 ... quantitation, and customizable end-point analysis. The system ...
... , CapSure HS and CapSure Macro LCM ... of populations of pure cells from tissue ... Microdissection., Ensure the Integrity of Microdissected ... CapSure LCM Caps have a patented transfer ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... highly sensitive laser confocal systems designed for ... scanners that meet your expectations, differentiating between ... optimizing the signal on the bottom as ... range for increased sensitivity. Results with VersArray ...
Biology Products: